These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Fragment-Based Design of Mycobacterium Tuberculosis InhA Inhibitors

revised on 02.01.2020, 13:39 and posted on 02.01.2020, 17:09 by Mohamad Sabbah, Vitor Mendes, Robert G. Vistal, David M. G. Dias, Monika Záhorszká, Katarina Mikušová, Jana Korduláková, Anthony Coyne, Tom. L. Blundell, Chris Abell

Tuberculosis (TB) remains a leading cause of mortality amongst infectious diseases worldwide. InhA, an enoyl ACP-reductase, has been the focus of numerous drug discovery efforts as this is the target of the first line pro-drug isoniazid. However, with resistance to this drug becoming more common the aim has been to find new clinical candidates that directly inhibit this enzyme and that do not require activation by the catalase peroxidase KatG, thus circumventing the majority of the resistance mechanisms. In this work, the screening and validation of a fragment library is described and development of the fragment hits using a fragment growing strategy was employed which led to the development InhA inhibitors with affinities of up to 250 nM.


Email Address of Submitting Author


University of Cambridge


United Kingdom

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest

Version Notes

Version 1.1


Read the published paper

in Journal of Medicinal Chemistry